Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 19 to 75

Comparing two treatments for patients with complex coronary lesions undergoing PCI

Official title: Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)

Run by Samsung Medical Center · NCT04014803 · Data updated 2026-11-12

This study is testing whether using aspirin with prasugrel or aspirin with clopidogrel is better for people with complex heart issues who are having a procedure to open blocked arteries.

Quick facts

PhasePhase 4
Study typeInterventional
Ages19 Years to 75 Years
SexAll
Enrollment3500 (estimated)
SponsorSamsung Medical Center
Academic / other
Locations2 sites (Seoul and 1 other locations)
StatusRecruiting
StartedJanuary 13, 2020
Main results expectedJune 30, 2027
Study endsDecember 31, 2028
Registry record updatedFebruary 9, 2026
Trial IDNCT04014803 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients aged 19 and older undergoing elective PCI for complex coronary lesions.

Probably not a fit

Patients with non-complex coronary lesions or those not undergoing PCI may not receive benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of dual antiplatelet therapy using aspirin combined with prasugrel versus aspirin combined with clopidogrel in patients undergoing elective percutaneous coronary intervention (PCI) for complex coronary lesions. It is a prospective, open-label, two-arm, randomized multicenter trial aimed at reducing ischemic events in this high-risk population. The study will assess the optimal duration of treatment and the potential benefits of using a more potent P2Y12 inhibitor in conjunction with aspirin. Participants will be monitored for ischemic events and safety outcomes over the course of the treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies that significantly reduce the risk of ischemic events in patients with complex coronary lesions.

How similar studies have gone: Other studies have shown promising results with similar dual antiplatelet therapy approaches, indicating potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ① Subject must be at least 19 years of age
* ② Subject who can verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
* ③ Patients undergoing elective PCI as follows:

  1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5 mm size
  2. Chronic total occlusion (≥3 months) as target lesion
  3. PCI for unprotected left main disease (left main ostium, body, or distal bifurcation including non-true bifurcation lesions)
  4. Long coronary lesions (expected stent length ≥38 mm)
  5. Multi-vessel PCI (≥2 vessels treated at one PCI session)
  6. Multiple stent needed (≥3 stents per patient)
  7. In-stent restenosis lesion as target lesion
  8. Severely calcified lesion (encircling calcium in angiography)
  9. Ostial lesions of left anterior descending artery, left circumflex artery, or right coronary artery

Exclusion Criteria:

* ① Hemodynamic instability or cardiogenic shock
* ② Subjects with serious bleeding (Intracerebral hemorrhage, gastrointestinal bleeding, hematuria, hemoptysis, and etc.)
* ③ Previous history of intracerebral hemorrhage, transient ischemic attack, or stroke
* ④ Known hypersensitivity or contraindications to study medications (aspirin, clopidogrel, and prasugrel)
* ⑤ Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
* ⑥ Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
* ⑦ Patients presenting with biomarker positive acute coronary syndrome
* ⑧ Patients chronically taking prasugrel or ticagrelor (≥1 week)
* ⑨ Subjects ≥75 years of age or \<60 kg of body weight
* ⑩ Patients taking warfarin or novel oral anticoagulants (dabigatran, rivaroxaban, edoxaban, or apixaban)

  * Eligible patients will be randomly assigned to treatment arms, stratified by participating centers, presence of diabetes mellitus, and stent types.

Where it's running

  • Samsung Medical Center
    Seoul, South Korea
    Recruiting
  • Samsung Medical Center
    Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.